Cynosure Group LLC Sells 711 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Cynosure Group LLC reduced its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,925 shares of the medical instruments supplier’s stock after selling 711 shares during the quarter. Cynosure Group LLC’s holdings in LeMaitre Vascular were worth $365,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC raised its stake in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after buying an additional 36,850 shares during the last quarter. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after acquiring an additional 4,964 shares during the period. Copeland Capital Management LLC raised its position in shares of LeMaitre Vascular by 1.0% during the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock valued at $108,068,000 after acquiring an additional 11,318 shares during the last quarter. Congress Asset Management Co. lifted its stake in shares of LeMaitre Vascular by 2.6% in the 3rd quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after purchasing an additional 18,295 shares during the period. Finally, Driehaus Capital Management LLC boosted its position in shares of LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of recent analyst reports. JMP Securities upped their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Oppenheimer restated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Finally, Barrington Research boosted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Stock Up 0.4 %

NASDAQ:LMAT opened at $105.80 on Friday. The company has a market cap of $2.38 billion, a P/E ratio of 57.81, a price-to-earnings-growth ratio of 2.62 and a beta of 0.89. LeMaitre Vascular, Inc. has a twelve month low of $51.70 and a twelve month high of $109.58. The business has a 50 day moving average price of $95.18 and a two-hundred day moving average price of $87.68.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.